Top Stories
Revolution Medicines RAS Inhibitor Nearly Doubles Pancreatic Cancer Survival in Phase 3 Win
Revolution Medicines posted breakthrough Phase 3 RASolute 302 data for daraxonrasib in KRAS G12-mutated metastatic pancreatic ductal adenocarcinoma, with median overall survival reaching 13.2 months versus 6.7 months for standard chemotherapy (HR 0.40; p<0.0001), according to BioPharma Dive. The trial met both co-primary endpoints of PFS and OS in the KRAS G12-mutant population, representing one of the largest survival gains seen in pancreatic cancer in decades. Daraxonrasib is a RAS(ON) multi-selective inhibitor that targets a broad range of KRAS G12 variants, not limited to G12C alone. Revolution, which has been subject to buyout rumors throughout 2026, plans to seek FDA approval using a Commissioner's National Priority Voucher for an accelerated review pathway, per a Revolution Medicines press release. Full PFS figures and subgroup analyses are expected at the 2026 ASCO Annual Meeting. Revolution Medicines gains first-mover advantage in KRAS G12 pancreatic cancer Standard chemotherapy combinations face obsolescence in KRAS-mutated PDAC setting
Ideaya Uveal Melanoma Drug Hits Phase 2/3 Primary Endpoint, Eyes H2 2026 FDA Filing
Ideaya Biosciences and partner Servier achieved the primary endpoint in the Phase 2/3 OptimUM-02 registrational trial of darovasertib, a selective PKC inhibitor, in combination with crizotinib for first-line HLA-A*02:01-negative metastatic uveal melanoma, according to Fierce Biotech. The combination improved median PFS to 6.9 months versus 3.1 months for investigator's choice (HR 0.42; p<0.0001), with ORR of 37.1% versus 5.8%, including five complete responses, per an Ideaya press release. The companies plan to file an NDA in H2 2026, potentially seeking accelerated approval. Uveal melanoma represents a high unmet need indication affecting approximately 2,500 patients annually in the US. Servier maintains global commercialization rights outside the US under their partnership agreement. The PKC inhibition mechanism offers a novel approach distinct from current melanoma standards including PD-1 inhibitors and targeted BRAF therapies. Ideaya secures clear regulatory pathway in underserved uveal melanoma market Current uveal melanoma standards face competition from differentiated mechanism
J&J Leans on Cancer Portfolio Growth to Offset Major Stelara Patent Losses
Johnson & Johnson reported strong Q1 2026 results with revenue of $24.1 billion as its oncology franchise offset a 61.7% decline in Stelara sales due to biosimilar competition, according to BioPharma Dive. Oncology led the charge with DARZALEX reaching $4 billion in quarterly sales and strong double-digit growth for CARVYKTI, TECVAYLI, and TALVEY, per J&J's earnings release. J&J raised its full-year 2026 outlook despite an approximately 540-basis-point headwind from Stelara biosimilar erosion. The quarterly results demonstrate how major pharma companies are pivoting toward oncology growth drivers amid patent cliff pressures on legacy immunology blockbusters. Management emphasized oncology as a key pillar for future revenue growth as the company transitions away from Stelara dependence. J&J oncology division gains prominence within pharmaceutical portfolio Legacy immunology franchise loses strategic importance amid patent expirations
Pipeline Watch
The FDA granted priority review on April 13, 2026 for ifinatamab deruxtecan (I-DXd), a B7-H3-directed ADC co-developed by Daiichi Sankyo and Merck, in adult patients with previously treated extensive-stage small cell lung cancer, according to CancerNetwork. The PDUFA target action date is October 10, 2026. The BLA is based on results from the IDeate-Lung01 Phase 2 trial. I-DXd previously received breakthrough therapy designation in August 2025 for the same indication, per Daiichi Sankyo.
Allogene Therapeutics reported interim futility analysis data from the pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma on April 13, 2026, BioPharma Dive reported. The allogeneic (off-the-shelf) CAR-T showed 58.3% MRD negativity versus 16.7% in the observation arm, with plasma ctDNA decreasing by a median of 97.7% by Day 45. No cases of CRS, ICANS, or GvHD were reported, and 10 of 12 patients were managed outpatient, per an Allogene press release. The approach integrates cema-cel as a "7th cycle" of first-line therapy without altering existing treatment workflows. An interim EFS analysis is anticipated in mid-2027.
Regeneron and Telix announced a 50/50 cost and profit-sharing partnership to co-develop next-generation radiopharmaceutical therapies, per Regeneron investor relations. The collaboration combines Regeneron's antibody expertise with Telix's radiopharmaceutical platform, targeting multiple oncology indications. The deal structure suggests significant upfront investment from both companies in the emerging radioligand therapy space.
A new trial compares stereotactic radiosurgery versus hippocampal-avoidant whole brain radiotherapy plus memantine for patients with 5 or more brain metastases, according to ClinicalTrials.gov. The study addresses a key clinical question about optimal radiation approaches for patients with multiple brain lesions, a growing population as systemic therapies improve.
Competitive Landscape
Revolution's daraxonrasib data positions the company ahead of Amgen's sotorasib and BMS's adagrasib (via Mirati acquisition, January 2024) in pancreatic cancer applications. Revolution gains first-mover advantage with strongest pancreatic PDAC survival data The HR of 0.40 (60% risk reduction) substantially exceeds historical benchmarks in this indication.
| Company | Drug | OS Improvement | Status |
|---|---|---|---|
| Revolution | daraxonrasib | HR 0.40 | Phase 3 success |
| Amgen | sotorasib | TBD | Phase 3 ongoing |
| BMS (Mirati) | adagrasib | TBD | Phase 2 |
J&J's Q1 results highlight how major pharmaceutical companies increasingly rely on cancer drug portfolios as immunology blockbusters face biosimilar competition, according to BioPharma Dive. Oncology divisions gain budget priority and strategic focus Legacy immunology franchises lose investment attention
The Regeneron-Telix radiopharmaceutical collaboration reflects growing big pharma investment in radioligand therapy as a distinct oncology modality alongside ADCs, per Regeneron announcements. The 50/50 partnership combines antibody and radiopharmaceutical expertise, suggesting radioligand approaches may become significant competitors to traditional ADC and small-molecule platforms.
Forward Looking
- Revolution Medicines plans to use a Commissioner's National Priority Voucher for accelerated FDA review; full data presentation expected at 2026 ASCO could trigger acquisition interest given unprecedented pancreatic cancer survival data.
- Ideaya H2 2026 FDA submission timeline positions potential uveal melanoma approval by mid-2027, creating first-mover advantage in underserved indication.
- I-DXd PDUFA target action date of October 10, 2026 could establish Daiichi Sankyo and Merck dominance across multiple solid tumor ADC applications.
- Allogene's ALPHA3 interim EFS analysis expected mid-2027 will be a key test of whether allogeneic CAR-T can deliver durable relapse prevention in first-line LBCL consolidation.
- Brain metastases radiation trial results may influence standard-of-care decisions for growing population of patients with multiple CNS lesions.